Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Capital Expenditures (2023 - 2025)

Historic Capital Expenditures for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $98000.0.

  • Contineum Therapeutics' Capital Expenditures rose 1951.22% to $98000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $355000.0, marking a year-over-year decrease of 4596.65%. This contributed to the annual value of $514000.0 for FY2024, which is 2415.46% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Capital Expenditures of $98000.0 as of Q3 2025, which was up 1951.22% from $44000.0 recorded in Q2 2025.
  • Over the past 5 years, Contineum Therapeutics' Capital Expenditures peaked at $309000.0 during Q4 2023, and registered a low of $22000.0 during Q3 2023.
  • In the last 3 years, Contineum Therapeutics' Capital Expenditures had a median value of $82000.0 in 2024 and averaged $101545.5.
  • Its Capital Expenditures has fluctuated over the past 5 years, first skyrocketed by 28387.1% in 2024, then crashed by 6802.72% in 2025.
  • Contineum Therapeutics' Capital Expenditures (Quarter) stood at $309000.0 in 2023, then crashed by 46.28% to $166000.0 in 2024, then tumbled by 40.96% to $98000.0 in 2025.
  • Its Capital Expenditures stands at $98000.0 for Q3 2025, versus $44000.0 for Q2 2025 and $47000.0 for Q1 2025.